Abstract
Introduction
BRCA mutation testing allows index patients and their families to be provided with appropriate cancer risk-reduction strategies. Because of the low prevalence of BRCA mutations in unselected breast cancer patients and the high cost of genetic testing, it is important to identify the subset of women who are likely to carry BRCA mutations. In the present study, we examined the association between BRCA1/2 germline mutations and the immunohistochemical features of breast cancer.
Methods
In a retrospective review of 498 breast cancer patients who had undergone BRCA testing at Seoul National University Bundang Hospital between July 2003 and September 2012, we gathered immunohistochemical information on estrogen receptor (er), progesterone receptor (pr), her2 (human epidermal growth factor receptor 2), cytokeratin 5/6, egfr (epidermal growth factor receptor), and p53 status.
Results
Among the 411 patients eligible for the study, 50 (12.2%) had germline mutations in BRCA1 or BRCA2. Of the 93 patients with triple-negative breast cancer (tnbc), 25 with BRCA1/2 mutations were identified (BRCA1, 20.4%; BRCA2, 6.5%). On univariate analysis, er, pr, cytokeratin 5/6, egfr, and tnbc were found to be related to BRCA1 mutations, but on multivariate analysis, only tnbc was significantly associated with BRCA1 mutations. Among patients with early-onset breast cancer or with a family history of breast or ovarian cancer, BRCA1 mutations were significantly more prevalent in the tnbc group than in the non-tnbc group.
Conclusions
In the present study, tnbc was the only independent predictor of BRCA1 mutation in patients at high risk of hereditary breast and ovarian cancers. Other histologic features of basal-like breast cancer did not improve the estimate of BRCA1 mutation risk.
Keywords: Basal-like phenotype, BRCA1, BRCA2, triple-negative breast cancer
INTRODUCTION
Individuals with a BRCA1/2 genetic mutation are at high risk of developing breast, ovarian, prostate, pancreatic, and other cancers during their lifetime. The risks are 40%–80% for breast cancer, 11%–40% for ovarian cancer, 1%–10% for male breast cancer, and up to 39% for prostate cancer1,2. Identifying BRCA gene mutations is important so that cancer risk-reduction strategies can be provided both to the index patients and to their family members. However, because of the low prevalence of BRCA mutations in unselected breast cancer patients and the high cost of genetic testing, selecting appropriate subjects for testing is important. Many centres recommend genetic testing for women whose probability of harboring a BRCA gene mutation exceeds 10%3.
Recently, many studies have reported that, compared with other breast cancer subtypes, triple-negative breast cancer (tnbc)—that is, tumours negative for estrogen receptor (er), progesterone receptor (pr), and her2 (human epidermal growth factor receptor 2) on immunohistochemical (ihc) testing—is associated with a higher prevalence of BRCA1 mutations, especially in younger individuals4–6. The National Comprehensive Cancer Network guidelines include tnbc patients 60 years of age or less in the eligibility criteria for genetic testing7. However, the literature shows a wide range of variation in the prevalence of BRCA1 mutations in tnbc patients4,5,8. Several studies have reported that tnbc alone, without other risk factors, is not an appropriate independent criterion for genetic testing and have recommended that additional risk factors be evaluated9–11.
The ihc features of BRCA1-related breast cancer are similar to those of basal-like breast cancer, both usually displaying negativity for er, pr, and her2. Both are also characterized by overexpression of egfr (epidermal growth factor receptor) and basal cytokeratins, and by negativity for phosphate and tensin homologue (pten), which are considered to be predictors for BRCA1 mutation8,12–15.
We therefore studied the association between BRCA1/2 germline mutations and the ihc features of breast cancer to determine whether those features are independent predictors of BRCA1 mutations in Korean breast cancer patients.
METHODS
Our retrospective review considered 498 patients who were diagnosed with breast cancer and underwent BRCA1/2 genetic testing at Seoul National University Bundang Hospital between July 2003 and September 2012. Of those patients, 82 with ductal carcinoma in situ or microinvasive carcinoma were excluded from the analysis. Among the patients who had undergone BRCA genetic testing, 5 were also excluded because they were not the index patient in their family. Thus, the final analysis was based on 411 index patients with invasive breast cancer. Personal and family histories of breast or ovarian cancer and age at the time of diagnoses of breast cancer were obtained from medical records, and ihc findings about hormone receptor, her2, cytokeratin 5/6 (CK5/6), egfr, and p53 status were obtained from pathology reports. The study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB no. B-1212/184-301).
BRCA1/2 Analysis
All patients met at least one of the following testing criteria for BRCA mutational screening: breast cancer patient with a family history of breast or ovarian cancer, patient with early-onset breast cancer (age at diagnosis ≤ 40 years), bilateral breast cancer, multi-organ cancer, or male breast cancer. The median interval between breast cancer diagnosis and genetic testing was 15 days. BRCA1 and BRCA2 mutation analyses were performed by direct dna sequencing and multiplex ligation-dependent probe amplification.
IHC Analysis
Expression of standard biomarkers including er, pr, her2, and p53 was evaluated in formalin-fixed paraffin-embedded whole-tissue sections at the time of diagnosis. Cytokeratin 5/6 and egfr were evaluated later in the course of the present study. Formalin-fixed paraffin-embedded tissue sections (4 μ m) were dried, deparaffinized, and rehydrated using standard procedures. Staining for ihc was performed on a BenchMark XT autostainer (Ventana Medical Systems, Tucson, AZ, U.S.A.) and an i-View detection kit (Ventana Medical Systems) for er (1:100, clone SP1: Lab Vision Corporation, Fremont, CA, U.S.A.), pr (1:70, pgr 636: Dako Corporation, Glostrup, Denmark), her2 (1:700, polyclonal: Dako Corporation), p53 (1:600, D07: Dako Corporation), and CK5/6 (1:50, clone D5/16 B4: Dako Corporation). Expression of egfr was detected using EGFR pharmDx (Dako Corporation).
Triple-negative breast cancer was defined as ihc negativity for er, pr, and her2. A cut-off value of less than 1% was used to determine er and pr negativity. Negative her2 status was accepted when ihc was scored as 0 or 1+ or when her2 was not detected by fluorescence in situ hybridization or silver in situ hybridization. Although samples from 3 patients whose her2 ihc score was 2+ were not tested by either fluorescence or silver in situ hybridization, all were er-positive, and the patients were therefore classified as non-tnbc. Positivity for egfr was accepted when ihc was scored 2+ or 3+. Positivity for CK5/6 was accepted if any invasive tumour cells showed cytoplasmic staining. Of the 93 tnbc patients, 68 with adequate formalin-fixed paraffin-embedded tissue blocks were examined for pten negativity using an anti-pten antibody (Y184: GeneTex, Irvine, CA, U.S.A.). Negativity for pten was accepted if pten staining was undetectable in tumour cells when compared with adjacent normal stromal cells.
Statistical Analysis
Prevalence of BRCA1/2 mutations was analyzed according to ihc features and was compared between the tnbc and non-tnbc groups on the basis of family history and age, using the Pearson chi-square test or Fisher exact test. Multivariate analysis by logistic regression was performed to estimate the value of selected variables to predict for BRCA1 or BRCA2 mutation. All statistical tests were performed using the IBM SPSS Statistics software application (version 21.0: IBM, Armonk, NY, U.S.A.). A p value less than 0.05 was considered to be statistically significant.
RESULTS
Characteristics of the Study Population
Table i presents the characteristics of the study population. Of the 411 eligible patients, 50 (12.2%) had germline mutations in BRCA1 (6.1%) or BRCA2 (6.1%). In patients with a family history of breast cancer, the rate of BRCA1/2 mutation was 18.9%; in patients with a family history of ovarian cancer, the rate was 42.1%. The prevalence of BRCA1/2 mutation was 12.9% in early-onset patients and 19.6% in patients with bilateral breast cancer. However, when patients with a family history were excluded, the rate of BRCA1/2 mutation was 8.8% in early-onset patients and 10.0% in patients with bilateral breast cancer. There was no difference in mean age between patients with BRCA1/2 mutation and those with no mutation (40.7 years vs. 42.7 years, p = 0.281); but patients with BRCA1 mutation were younger than those with no mutation (34.8 years vs. 42.7 years, p < 0.001).
TABLE I.
Characteristics of the study population by mutation status
| Characteristic | Overall | BRCA1 | BRCA2 | BRCA1/2 | Non-BRCA | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
||||||
| (n) | (%) | (n) | (%) | (n) | (%) | (n) | (%) | (n) | (%) | |
| Overall cohort | 411 | 100.0 | 25 | 6.1 | 25 | 6.1 | 50 | 12.2 | 361 | 87.8 |
| Mean age (years) | 42.5 | 34.8 | 46.6 | 40.7 | 42.7 | |||||
| Early onset (≤35 years) | 155 | 37.7 | 13 | 8.4 | 7 | 4.5 | 20 | 12.9 | 135 | 87.1 |
| Bilateral breast cancer | 46 | 11.2 | 4 | 8.7 | 5 | 10.9 | 9 | 19.6 | 37 | 80.4 |
| Family history | ||||||||||
| Breast cancer only | 161 | 39.2 | 11 | 6.8 | 15 | 9.3 | 26 | 16.1 | 135 | 83.9 |
| Ovarian cancer only | 11 | 2.7 | 4 | 36.3 | 1 | 9.1 | 5 | 45.5 | 6 | 54.5 |
| Both breast and ovarian cancer | 8 | 1.9 | 1 | 12.5 | 2 | 25.0 | 3 | 37.5 | 5 | 62.5 |
| No family history | ||||||||||
| Early onset (≤35 years) | 135 | 32.8 | 6 | 4.4 | 6 | 4.4 | 12 | 8.8 | 123 | 91.2 |
| Bilateral breast cancer | 30 | 7.3 | 2 | 6.7 | 1 | 3.3 | 3 | 10.0 | 27 | 90.0 |
| Both breast and ovarian cancer | 4 | 1.0 | 1 | 25.0 | 1 | 25.0 | 2 | 50.0 | 2 | 50.0 |
| Multiple organ cancer, except ovarian cancer | 14 | 3.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 14 | 100.0 |
IHC Features of BRCA1 and BRCA2 Tumours
Table ii shows the frequency of BRCA mutations according to expression of CK5/6, egfr, p53, er, pr, her2, and tnbc. On univariate analysis, statistically significant differences in BRCA1 mutation rates were observed depending on the expression of CK5/6, egfr, er, pr, and tnbc. No difference in the prevalence of BRCA2 mutations in the presence of a basal-like phenotype were observed (Table ii). To identify independent predictors of BRCA1 mutation, we performed a multivariate analysis based on CK5/6, egfr, p53, and tnbc. On multivariate analysis, er, pr, and her2 were excluded because they interacted with tnbc, and only tnbc showed an association with BRCA1 mutations (Table iii).
TABLE II.
Univariate analysis of the immunohistologic features of basal-like breast cancer and BRCA1/2 mutations
| Feature and status | Overall (n) | BRCA1 | BRCA2 | Non-BRCA | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||
| (n) | (%) | p Value | (n) | (%) | p Value | (n) | (%) | |||
| CK5/6 | Negative | 143 | 6 | 4.2 | 0.002 | 11 | 7.7 | 0.299 | 126 | 88.1 |
| Positive | 46 | 9 | 19.6 | 1 | 2.2 | 36 | 78.2 | |||
| EGFR | Negative | 199 | 10 | 5.0 | 0.020 | 17 | 8.5 | 0.082 | 172 | 86.5 |
| Positive | 60 | 9 | 15.0 | 1 | 1.7 | 50 | 83.3 | |||
| p53 | Negative | 292 | 15 | 5.1 | 0.209 | 22 | 7.5 | 0.054 | 255 | 87.4 |
| Positive | 119 | 10 | 8.4 | 3 | 2.5 | 106 | 89.1 | |||
| ER | Negative | 136 | 20 | 14.7 | <0.001 | 6 | 4.4 | 0.385 | 110 | 80.9 |
| Positive | 275 | 5 | 1.8 | 19 | 6.9 | 251 | 91.3 | |||
| PR | Negative | 173 | 20 | 11.6 | <0.001 | 10 | 5.8 | 0.827 | 143 | 82.6 |
| Positive | 238 | 5 | 2.1 | 15 | 6.3 | 218 | 91.6 | |||
| HER2 | Negative | 311 | 23 | 7.4 | 0.056 | 24 | 7.7 | 0.017 | 264 | 84.9 |
| Positive | 97 | 2 | 2.1 | 1 | 1.0 | 94 | 96.9 | |||
| TNBC | Negative | 318 | 6 | 1.9 | <0.001 | 19 | 6.0 | 0.866 | 293 | 92.1 |
| Positive | 93 | 19 | 20.4 | 6 | 6.5 | 68 | 73.1 | |||
CK5/6 = cytokeratin 5/6; EGFR = epidermal growth factor receptor; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; TNBC = triple-negative breast cancer.
TABLE III.
Multivariate analysis of the immunohistologic features of basal-like breast cancer and BRCA1/2 mutation
| Feature | BRCA1 | BRCA1/2 | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| OR | 95% CI | p Value | OR | 95% CI | p Value | |
| CK5/6 | 1.909 | 0.357 to 10.195 | 0.450 | 1.469 | 0.360 to 5.986 | 0.592 |
| EGFR | 0.624 | 0.161 to 2.414 | 0.494 | 0.428 | 0.118 to 1.556 | 0.198 |
| p53 | 0.682 | 0.192 to 2.425 | 0.555 | 0.496 | 0.169 to 1.450 | 0.200 |
| TNBC | 6.922 | 1.183 to 40.492 | 0.032 | 3.627 | 0.851 to 15.450 | 0.081 |
OR = odds ratio; CI = confidence interval; CK5/6 = cytokeratin 5/6; EGFR = epidermal growth factor receptor; TNBC = triple-negative breast cancer.
Comparison of BRCA Mutation Rates in TNBC and Non-TNBC Patients
BRCA1/2 mutations were significantly more prevalent in tnbc patients than in non-tnbc patients (26.9% vs. 7.9%, p < 0.001). In patients with a family history of breast or ovarian cancer, the prevalence of BRCA1/2 mutations was higher in those with tnbc than in those with non-tnbc regardless of age at diagnosis with breast cancer (40.0% vs. 11.9%, p < 0.001). In patients without a family history of breast or ovarian cancer, the overall prevalence of BRCA1/2 mutation was also higher in patients with tnbc than in those with non-tnbc (14.6% vs. 4.9%, p = 0.027). The prevalence of BRCA1 mutations was significantly higher in patients with tnbc than in those with non-tnbc (20.4% vs. 1.9%, p < 0.001), but the prevalence of BRCA2 mutations was not different in patients with tnbc and with non-tnbc (6.5% vs. 6.0%, p = 0.866). When patients were divided by age group (younger and older than 35 years), the BRCA1 mutation rate was higher in patients with tnbc than with non-tnbc in both age groups (Table iv); however, in the case of patients more than 35 years of age, the difference in prevalence between patients with tnbc and with non-tnbc was not statistically significant (13.3% vs. 1.2%, p = 0.063).
TABLE IV.
Comparison of BRCA mutation rates according to triple-negative breast cancer status
| Characteristic | Triple negative status [n (%)] | Non–triple negative status [n (%)] | p Value for … | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||||
| Pts | BRCA1 | BRCA2 | Total BRCA | Pts | BRCA1 | BRCA2 | Total BRCA | BRCA1/2 | BRCA1 | BRCA2 | |
| Overall cohort | 93 | 19 (20.4) | 6 (6.5) | 25 (26.9) | 318 | 6 (1.9) | 19 (6.0) | 25 (7.9) | <0.001 | <0.001 | 0.866 |
| With family history | |||||||||||
| Early onset (≤35 years) | 13 | 7 (53.9) | 0 (0.0) | 7 (53.9) | 7 | 0 (0.0) | 1 (14.3) | 1 (14.3) | 0.158 | 0.044 | 0.350 |
| >35 Years | 32 | 6 (18.8) | 5 (15.6) | 11 (34.4) | 128 | 3 (2.3) | 12 (9.4) | 15 (11.7) | 0.002 | 0.002 | 0.337 |
| Total | 45 | 13 (28.9) | 5 (11.1) | 18 (40.0) | 135 | 3 (2.2) | 13 (9.6) | 16 (11.9) | <0.001 | <0.001 | 0.777 |
| Without family history | |||||||||||
| Early onset (≤35 years) | 33 | 4 (12.1) | 1 (3.0) | 5 (15.2) | 102 | 2 (2.0) | 5 (4.9) | 7 (6.9) | 0.165 | 0.031 | 1.000 |
| >35 Years | 15 | 2 (13.3) | 0 (0.0) | 2 (13.3) | 81 | 1 (1.2) | 1 (1.2) | 2 (2.5) | 0.114 | 0.063 | 1.000 |
| Total | 48 | 6 (12.5) | 1 (2.1) | 7 (14.6) | 183 | 3 (1.6) | 6 (3.3) | 9 (4.9) | 0.027 | 0.003 | 1.000 |
Pts = patients.
BRCA Mutation Rates According to PTEN Status in Patients with TNBC
Of the 68 patients tested for pten status, 37 (54.4%) were pten-negative, and 31 (45.6%) showed intact pten staining. The prevalence of BRCA1 and BRCA2 mutations did not differ by pten status (BRCA1: 18.9% vs. 25.8%, p = 0.495; BRCA2: 10.8% vs. 6.5%, p = 0.684). Similarly, the prevalence of BRCA1 or BRCA2 mutation did not differ between the groups when they were stratified by family history of breast or ovarian cancer (Table v).
TABLE V.
Prevalence of BRCA1/2 mutations by PTEN (phosphate and tensin homologue) status in patients with triple-negative breast cancer (TNBC)
| PTEN status | BRCA status [n (%)] | p Value for … | |||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| All | BRCA1 | BRCA2 | Non-BRCA | BRCA1/2 | BRCA1 | BRCA2 | |
| All with TNBC | 68 | 15 (22.1) | 6 (14.7) | 47 (69.1) | 0.822 | 0.495 | 0.684 |
| Loss | 37 | 7 (18.9) | 4 (10.8) | 26 (70.3) | |||
| Intact | 31 | 8 (25.8) | 2 (6.5) | 21 (67.7) | |||
| With family history | 34 | 10 (29.4) | 5 (14.7) | 19 (55.9) | 0.730 | 1.000 | 1.000 |
| Loss | 17 | 5 (29.4) | 3 (17.6) | 9 (53.0) | |||
| Intact | 17 | 5 (29.4) | 2 (11.8) | 10 (58.8) | |||
| Without family history | 34 | 5 (14.7) | 1 (2.9) | 28 (82.4) | 0.672 | 0.627 | 1.000 |
| Loss | 20 | 2 (10.0) | 1 (5.0) | 17 (85.0) | |||
| Intact | 14 | 3 (21.4) | 0 (0.0) | 11 (78.6) | |||
Pts = patients.
DISCUSSION
In the present study, we evaluated the association between ihc features of breast cancer and BRCA mutation in a Korean population. We observed that, on univariate analysis, CK5/6, egfr, er, pr, and tnbc were associated with BRCA1 mutation. However, on multivariate analysis, only tnbc was predictive of BRCA1 mutation. No association between the basal-like phenotype and BRCA2 mutation was observed.
Since the recognition that BRCA1-related breast cancer is similar to basal-like breast cancer, several studies have suggested that features of basal-like breast cancer might help to identify carriers of BRCA1 mutations. Foulkes et al.8 observed CK5/6 expression in 15 of 17 (88%) BRCA1-related breast cancers negative for er and her2, finding that expression of CK5/6 was associated with BRCA1 mutation. However, their study was limited to Ashkenazi Jewish women, and only breast cancer specimens negative for er and her2 underwent immunostaining for CK5/6. In our study, CK5/6 was associated with BRCA1 breast cancer on univariate analysis, but that association was not statistically significant on multivariate analysis. Lakhani and colleagues12 compared 182 BRCA1 carriers with 109 control subjects and evaluated cytokeratins (CK14, CK5/6, CK17), osteonectin, and egfr expression as independent predictors of BRCA1 mutation. They found that er negativity and CK14 and CK5/6 expression were independent markers of BRCA1 mutation, suggesting that cytokeratin staining and er status, combined with a family history of breast or ovarian cancer, might more accurately predict the probability of carrying a BRCA1 mutation. Collins et al.16 reported that the expression of basal cytokeratins and egfr could help to identify a subset of tnbc patients with a basal-like phenotype, but was not sufficient to identify women with tnbc who were likely to carry a germline BRCA1 mutation. Similarly, in our study, the basal-like phenotype was associated with BRCA1 mutation, but tnbc was the only significant predictive variable on multivariate analysis.
Several studies have reported that loss of pten expression is significantly associated with basal-like breast cancer and BRCA1-associated hereditary breast cancer13,15. Phuah et al.17 evaluated pten status for 26 tnbc patients and reported that the addition of 2 criteria (triple negativity and pten status) improved the sensitivity of the Manchester scoring method, suggesting that pten status could improve the identification of BRCA1 mutation carriers. We therefore evaluated pten status in 68 tnbc patients and compared the prevalence of BRCA1 mutations in the pten-intact and pten-negative groups. No difference between those groups was observed in our study. Whether loss of pten expression is associated with BRCA1-related breast cancer is still controversial, and further studies involving larger patient cohorts will be required to address this question.
Several studies have examined the prevalence of BRCA mutations in unselected tnbc patients18–21, and their authors have suggested that tnbc patients should be considered for BRCA1 and BRCA2 genetic testing based on the evidence of high BRCA mutation prevalence in unselected tnbc patients. Muendlein et al.18 assessed the prevalence of BRCA mutation in 100 unselected tnbc patients. They observed a 21% rate of BRCA mutation, and calculated that 38.1%–52.4% of BRCA1/2 mutation carriers would be missed under the current German and Austrian national guidelines for genetic testing, which do not include tnbc as a genetic testing criterion. Villarreal-Garza et al.19 investigated 190 unselected Mexican women with tnbc at the age of 50 years or younger. They found that the prevalence of BRCA mutations was 30.3% in women who were diagnosed at the age of 40 years or younger and 18.3% in those diagnosed between the ages of 41 and 50 years. Sharma et al.20 reported that the prevalence of BRCA mutations was 15.4% in 207 unselected tnbc patients in a study that incorporated stratification by significant family history and age at diagnosis. In their multivariate model, the probability of a BRCA mutation in a patient with significant family history and diagnosis at age 51 was 29.5%, which was much higher than the 5.3% for a patient with no significant family history and diagnosis at age 51. Couch et al.21 analyzed 1824 tnbc patients unselected for family history of breast or ovarian cancer and found that 14.6% of the overall group carried deleterious germline mutations, with 11.2% having mutations in BRCA1 (8.5%) and BRCA2 (2.7%). They also analyzed the prevalence of BRCA mutation by family history of cancer and age. With no family history of cancer, the prevalence of BRCA1/2 mutation was 19.8%, 15.4%, 8.6%, 7.5%, and 1.4% in patients diagnosed at less than 35 years of age, 35–39 years of age, 40–49 years of age, 50–59 years of age, and more than 60 years of age respectively.
Although the prevalence of BRCA mutation was high for unselected tnbc patients in most studies, those studies included high-risk subjects with a significant family history and early-onset breast cancer, which could result in an overestimation of the BRCA mutation prevalence. The identification of BRCA mutations in tnbc patients can have a significant effect on treatment. Compared with patients having other breast cancer subtypes, those with tnbc often have a worse prognosis22, and no suitable targeted therapy has been developed for tnbc patients. However, the pathologic complete response rate reached 83% after cisplatin neoadjuvant chemotherapy in patients with BRCA1-related breast cancer23. Moreover, in carriers of BRCA1 or BRCA2 mutations, treatment with inhibitors of parp (poly adp ribose polymerase) has shown antitumour activity, leading to synthetic lethality in tumour cells24. Thus, the BRCA mutation status of patients with tnbc might be a predictor of response to those therapies.
Based on recent studies, it therefore seemed important to identify whether tnbc should be incorporated into Korean genetic testing criteria. In the present study, we found that tnbc is an independent predictor of BRCA1 mutation in patients at high risk of hereditary breast and ovarian cancer. Given a positive family history, the BRCA1 mutation rate was much higher in patients with tnbc than in those with non-tnbc (28.9% vs. 2.2%, p < 0.001). Even in tnbc patients more than 35 years of age with no family history, the BRCA1 mutation rate was more than 10%. Nevertheless, their mutation rate was not statistically significantly different from the rate for their non-tnbc counterparts (13.3% vs. 1.2%, p = 0.063). Our results suggest that tnbc might play an important role in stratifying a patient’s risk of having a BRCA1 mutation, especially for patients with a family history of breast or ovarian cancer, or with early-onset breast cancer.
Our study has several limitations. First, in this single-institution study, the patient population was relatively small. The results might have differed if the study population had been larger. Second, the study was somewhat focused on high-risk patients, representing a possible selection bias. Lastly, ihc results for some patients, such as those for CK5/6 and egfr, were missing.
CONCLUSIONS
In patients at high risk of hereditary breast and ovarian cancer, tnbc is an independent predictor for BRCA1 mutation. Other ihc features of basal-like breast cancer did not improve the predictive estimates for BRCA1 mutation risk. More research is required to identify the subset of women who are at a greater risk of carrying a BRCA1 mutation.
ACKNOWLEDGMENTS
This research was supported by grant no. 02-2013-050 from the Seoul National University Bundang Hospital Research Fund.
CONFLICT OF INTEREST DISCLOSURES
We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.
REFERENCES
- 1.Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30. doi: 10.1086/375033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lorenzo Bermejo J, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol. 2004;15:1834–41. doi: 10.1093/annonc/mdh474. [DOI] [PubMed] [Google Scholar]
- 3.U.K. National Institute for Health and Care Excellence (nice) Familial Breast Cancer: Classification, Care and Managing Breast Cancer and Related Risks in People with a Family History of Breast Cancer. London, UK: NICE; 2013. [Available online at: https://www.nice.org.uk/guidance/cg164; cited 16 August 2014] [PubMed] [Google Scholar]
- 4.Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082–9. doi: 10.1158/1078-0432.CCR-10-2560. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787–95. doi: 10.1002/cncr.26576. [DOI] [PubMed] [Google Scholar]
- 6.Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28:4214–20. doi: 10.1200/JCO.2010.28.0719. [DOI] [PubMed] [Google Scholar]
- 7.National Comprehensive Cancer Network (nccn) NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian Ver 12014. Fort Washington PA: NCCN; 2014. [Current version available online at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (free registration required); cited 8 August 2016] [Google Scholar]
- 8.Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482–5. doi: 10.1093/jnci/djg050. [DOI] [PubMed] [Google Scholar]
- 9.Rummel S, Varner E, Shriver CD, Ellsworth RE. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat. 2013;137:119–25. doi: 10.1007/s10549-012-2348-2. [DOI] [PubMed] [Google Scholar]
- 10.Robertson L, Hanson H, Seal S. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106:1234–8. doi: 10.1038/bjc.2012.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Seong MW, Kim KH, Chung IY, et al. on behalf of the Korean Hereditary Breast Cancer Study Group A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients. Breast Cancer Res Treat. 2014;146:63–9. doi: 10.1007/s10549-014-3006-7. [DOI] [PubMed] [Google Scholar]
- 12.Lakhani SR, Reis-Filho JS, Fulford L, et al. on behalf of the Breast Cancer Linkage Consortium Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175–80. doi: 10.1158/1078-0432.CCR-04-2424. [DOI] [PubMed] [Google Scholar]
- 13.Saal LH, Gruvberger-Saal SK, Persson C, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient dsb repair. Nat Genet. 2008;40:102–7. doi: 10.1038/ng.2007.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25:5846–53. doi: 10.1038/sj.onc.1209876. [DOI] [PubMed] [Google Scholar]
- 15.Martins FC, De S, Almendro V, et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2012;2:503–11. doi: 10.1158/2159-8290.CD-11-0325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Collins LC, Martyniak A, Kandel MJ, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol. 2009;33:1093–7. doi: 10.1097/PAS.0b013e31819c1c93. [DOI] [PubMed] [Google Scholar]
- 17.Phuah SY, Looi LM, Hassan N, et al. Triple-negative breast cancer and pten (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer. Breast Cancer Res. 2012;14:R142. doi: 10.1186/bcr3347. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Muendlein A, Rohde BH, Gasser K, et al. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J Cancer Res Clin Oncol. 2015;141:2005–12. doi: 10.1007/s00432-015-1986-2. [DOI] [PubMed] [Google Scholar]
- 19.Villarreal-Garza C, Weitzel JN, Llacuachaqui M, et al. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150:389–94. doi: 10.1007/s10549-015-3312-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707–14. doi: 10.1007/s10549-014-2980-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304–11. doi: 10.1200/JCO.2014.57.1414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA. The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. Ann Surg Oncol. 2015;22:874–82. doi: 10.1245/s10434-014-4279-0. [DOI] [PubMed] [Google Scholar]
- 23.Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375–9. doi: 10.1200/JCO.2008.20.7019. [DOI] [PubMed] [Google Scholar]
- 24.Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34. doi: 10.1056/NEJMoa0900212. [DOI] [PubMed] [Google Scholar]